Form 4: ZVRA Director Secor Granted 45,000 Stock Options

Zevra Therapeutics Director Alicia Secor was granted 45,000 stock options with an exercise price of $8.17, vesting over three years or upon a change in control.

Summary

• Alicia Secor, a Director of ZEVRA THERAPEUTICS, INC. (ZVRA), was granted 45,000 stock options.
• The options have an exercise price of $8.17 per share, which was the closing price of the company's common stock on the Nasdaq Global Select Market on the grant date.
• The grant date for these options was December 2, 2025.
• The options will vest in three equal installments, one day prior to each of the first three annual stockholder meetings following the grant date, or immediately prior to a Change in Control.
• Vesting is contingent upon Ms. Secor's continued service as a director.
• The options expire on December 1, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a neutral to slightly positive event, as it aligns interests and provides incentive, but does not reflect immediate operational or financial performance. It's a standard compensation practice.

Positives

• The grant of 45,000 stock options to a director aligns the director's interests with long-term shareholder value creation.
• The exercise price of $8.17, equal to the closing market price on the grant date, indicates a standard at-the-money option grant, providing incentive for future stock price appreciation.
• The vesting schedule, tied to continued service and potential change in control, promotes retention and incentivizes strategic oversight.

Negatives

• No immediate cash inflow for the director, as these are options, not stock awards.
• The value of the options is entirely dependent on the future performance of ZVRA's stock price exceeding the $8.17 exercise price.

Risks

• The value of the stock options is subject to market fluctuations and the company's future performance. If the stock price does not rise above $8.17, the options may expire worthless.
• Vesting is contingent on continued service, meaning the director would forfeit unvested options if service ceases before vesting conditions are met.

Future Outlook

The vesting schedule for the stock options, tied to future annual stockholder meetings and a potential Change in Control, indicates a long-term incentive structure for the director, aligning with the company's future strategic direction and potential corporate events.

Industry Context

This Form 4 filing is a routine disclosure of an equity grant to a director, common practice in the biotechnology and pharmaceutical industry to incentivize leadership and align their interests with long-term company performance and shareholder value. Such grants are a standard component of executive and director compensation packages across publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact through increased alignment of director incentives with long-term stock performance.

Next Steps

• The stock options will vest in three equal installments, one day prior to the first three annual stockholder meetings occurring after the grant date.
• The options will also vest immediately prior to a Change in Control, subject to the director's continued service.

Key Dates

Recommendation

This Form 4 filing reports a routine stock option grant to a director, which is a standard component of executive compensation designed to align interests with shareholders. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive company updates.

Keywords

ZVRA, Zevra Therapeutics, Stock Options, Form 4, Director Compensation, Equity Grant, Beneficial Ownership, SEC Filing, Corporate Governance